GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Buyback Yield %

NetraMark Holdings (XCNQ:AIAI) Buyback Yield % : 0.00 (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

NetraMark Holdings's current buyback yield was 0.00%.


NetraMark Holdings Buyback Yield % Historical Data

The historical data trend for NetraMark Holdings's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Buyback Yield % Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Buyback Yield %
- -15.37 -4.51 -15.72

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.07 -12.76 - - -

Competitive Comparison of NetraMark Holdings's Buyback Yield %

For the Health Information Services subindustry, NetraMark Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NetraMark Holdings's Buyback Yield % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's Buyback Yield % falls into.



NetraMark Holdings Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

NetraMark Holdings's Buyback Yield for the fiscal year that ended in Sep. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 3.972) / 25.2705915
=-15.72%

NetraMark Holdings's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 20.14608
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.


NetraMark Holdings Buyback Yield % Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings (XCNQ:AIAI) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Andrew Parks Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines